Gilead Sciences (GILD) stock surged 5.82% in the pre-market session on Wednesday, driven by the company's strong financial performance in the fourth quarter of 2024 and positive outlook for its HIV and oncology franchises.
The biopharmaceutical giant reported a 13% year-over-year increase in total product sales, excluding Veklury, to $7.2 billion for the fourth quarter. This impressive growth was primarily fueled by its HIV segment, where sales jumped 16% driven by the continued strength of Biktarvy, a leading HIV treatment that saw a 21% increase in demand.
Gilead's oncology portfolio also contributed significantly to the robust performance, with sales of its breast cancer drug Trodelvy climbing 24% year-over-year. The company's newly launched primary biliary cholangitis (PBC) treatment, Livdelzi, exceeded expectations in its first full quarter of commercial availability, further bolstering Gilead's liver disease franchise.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.